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AbsTrACT
The gut–liver axis describes the complex interactions 
between gut microbiota, the small and large bowel, the 
immune system and the liver. Current evidence associates 
abnormalities within the gut–liver axis with liver disease 
such as primary sclerosing cholangitis (PSC). PSC is 
believed to be an immune-mediated disease though the 
exact mechanism of its pathogenesis remains unknown. 
Here, we report a case of a 66 -year-old woman with 
treatment-resistant ulcerative colitis and PSC which 
continued to be active following subtotal colectomy. 
Interestingly, her PSC achieved full remission after 
proctectomy for treatment-resistant proctitis in the rectal 
stump. This case report supports existing hypotheses 
that PSC is an immune-mediated disease triggered by 
antigens within the gut. More notably, it suggests the 
yet unidentified pathogens may be localised to the lower 
gastrointestinal tract including the rectum.
IntroductIon
The gut–liver axis, a concept thought to 
be first introduced in 1987 by Volta et al,1 2 
describes the complex interactions between 
gut microbiome, the small and large bowel, 
the immune system and the liver. The gut–
liver axis plays an important role in the patho-
genesis of primary sclerosing cholangitis 
(PSC).3 PSC, an immune-mediated disease, 
involves chronic inflammation of both intra-
hepatic and extrahepatic bile ducts, leading 
to liver cirrhosis. Approximately 47%–76% of 
patients with PSC also suffer from inflamma-
tory bowel disease (IBD)4 though no causal 
link has been established. Gut microbiome 
dysbiosis, increased intestinal permeability, 
translocation of circulating proinflammatory 
cytokines in the portal vein and circulating 
autoantibodies are hallmark features in the 
pathophysiology of PSC3, however, little 
else is known about the triggering microor-
ganism, antigen or its location.
Here, we describe the remission of 
persistently active PSC in a patient with 
ulcerative colitis (UC) only after interfer-
ence of the lower gut–liver axis by means 
of a two-staged panproctocolectomy. This 
suggests that the immune-mediated response 
in PSC is triggered by gut-specific pathogens, 
and these are localised in the lower gastroin-
testinal tract (GI) including the rectum.
case presentatIon
A 66-year-old woman presented to the surgical 
outpatient clinic with a 2-month history of 
bright red rectal bleeding and intermittent 
diarrhoea. No history of weight loss, foreign 
travel or dietary change was reported. She 
suffered from hypertension but had no other 
comorbidities. She took amlodipine daily and 
did not drink alcohol or smoke. No signifi-
cant family history was elicited.
Physical examination was unremark-
able, and routine blood tests were normal. 
A flexible sigmoidosopy however demon-
strated mild–moderate inflammation from 
the rectum to the rectosigmoid junction, 
and biopsies taken showed features consis-
tent with moderately active UC (see online 
supplementary file 1). The patient was subse-
quently started on oral and topical 5-amino-
salicylic acids (5-ASAs), but in the following 
months, her UC worsened and her liver func-
tion tests began to rise. Within a year after 
first presentation, oral steroid therapy in 
combination with 5-ASAs failed to control the 
patient's UC, and she was admitted urgently 
to hospital and referred to the gastroenter-
ology department. However, despite intra-
venous steroids, antibiotics and ciclosporin 
rescue therapy, the patient's condition wors-
ened. Her care was transferred back to the 
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Figure 1 (A) Skin biopsy with diffuse dense neutrophil 
infiltration confirming diagnosis of pyoderma gangrenosum, 
H&E stain at x20 magnification. (B) Liver biopsy 
demonstrating onion skin appearance of periductal fibrosis 
highly suggestive for primary sclerosing cholangitis, Masson 
stain at x20 magnification.
surgical team, and a subtotal colectomy with loop ileos-
tomy was performed.
The subtotal colectomy was successful, and no compli-
cations of the surgery were experienced. However, 
shortly after discharge from hospital, the patient began 
to experience right upper quadrant pain and her liver 
function tests remained persistently raised. At this point, 
the surgeons referred the patient to a hepatologist for 
an opinion. PSC was suspected, and a full serological 
work up for liver disease was performed. This demon-
strated antiproteinase 3 antibody (cANCA) positivity 
only, and the rest of the serological panel was negative. 
An oesophagogastroduodenoscopy was performed and 
duodenal biopsies taken, both of which were reported 
as normal. A magnetic resonance cholangiopancreatog-
raphy (MRCP) demonstrated a gallstone in the neck of 
the gallbladder, but no features of cholangiopathy were 
observed. Given the negative pANCA result, normal 
biliary tree on MRCP and the patient's reluctance to have 
a liver biopsy following recent surgery, it was concluded 
that the cholestatic liver function tests were most likely 
due to gallstone disease. However, a repeat MRCP to 
exclude the progression of cholangiopathy was sched-
uled for 6 months time.
Over the next few months, the patient was referred 
to a dermatologist after she developed a violet rash 
near the site of the stoma and over her left lower limb. 
A punch biopsy was performed on the lesion on her 
lower limb, and the features of pyoderma gangrenosum 
were observed, see figure 1 (panel A). Subsequently, 
the repeat MRCP demonstrated a “double duct sign” 
(online supplementary file 2), but further CT imaging 
and endoscopic ultrasound ruled out a pancreatic lesion. 
Other causes for the double duct sign were not found 
in our investigations, and IgG4 disease was also excluded 
(normal IgG4 levels and no IgG4-positive plasma cells 
seen on biopsies). After discussion at a hepato-pancreato-
biliary specialist multidisciplinary meeting, the patient 
was referred for a liver biopsy as the clinical suspicion for 
PSC was high, and the patient's liver function tests were 
persistently elevated. The liver biopsy was performed 
uneventfully, and features of PSC were noted, see figure 1 
(panel B). The patient was treated with ursodeoxycholic 
acid (UCDA), however, this made little improvement to 
her cholestatic liver function tests.
Within the same year, the patient was seen in surgical 
outpatient clinic as a postoperative follow-up. She 
continued to suffer from ongoing inflammation in 
the rectum and remnants of the sigmoid colon (rectal 
stump) despite maximal medical treatment. Impor-
tantly, there were no symptoms or clinical evidence that 
suggested backwash ileitis. As a result, the patient opted 
for a total proctectomy with ileoanal pouch anastomosis. 
This was performed once again uneventfully, however, a 
few months later, the patient represented with symptoms 
of bowel obstruction. She then proceeded to have a lapa-
rotomy for a reversal loop ileostomy and adhesiolysis at 
site of ileoanal anastomosis. Interestingly, by this point, 
it was noted that the patient's liver function tests had 
improved significantly (figure 2).
The patient was eventually discharged from hospital 
and she continues to be monitored by the gastroenter-
ology department. Notably, 2 years after her panproc-
tocolectomy her liver function tests normalised. and 
she has remained asymptomatic. She remains reluctant 
to have further liver biopsies, but serial imaging of her 
liver and biliary tree to date have demonstrated complete 
resolution of the double duct sign and no evidence of 
chronic liver disease or portal hypertension that would 
suggest progression of PSC.
dIscussIon
The mechanism of pathogenesis in PSC remains poorly 
understood and this is reflected in the limited treatment 
options in clinical practice. Current animal models of 
PSC remain suboptimal, and to date, there is not a single 
animal model that displays all attributes of the disease 
seen in humans.5–7 Well-designed longitudinal studies 
offer alternative means to identify causative microorgan-
isms, however, the lack of a biomarker in early disease, 
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Figure 2 The effect of proctocolectomy on liver function tests in primary sclerosing cholangitis. bilirubin is not displayed 
because the patient never had an abnormal result. UC, ulcerative colitis.
low prevalence of the disease and poor accessibility of the 
biliary tree restrict the conduct of such studies.5 Observa-
tional studies such as case control and association studies, 
though do not demonstrate causality, still provide impor-
tant information and have contributed to much of our 
understanding of PSC.3
Similarly, this case report describes a series of longi-
tudinal observations in a patient over a 9-year period 
including the evolution and behaviour of the disease; 
from the diagnosis of UC, to the development of PSC 
and pyoderma gangrenosum, and subsequently the 
effects of partial and complete “knock out” of the lower 
GI tract by subtotal colectomy and total proctectomy. 
It is noteworthy that there are several distinct PSC-IBD 
phenotypes; the majority are patients with PSC-UC7 with 
backwash ileitis, rectal sparing disease or pancolitis.8–10 In 
this particular case, the patient suffered from pancolitis 
with rectal involvement. It was severe, treatment-resis-
tant pancolitis that was the indication for her colectomy, 
and there was little clinical evidence to suggest backwash 
ileitis before or after her surgery. Interestingly, the remis-
sion of PSC described in this case is preserved up until 
today, 7 years following proctectomy. Our observations 
suggest that the complete remission of PSC was success-
fully achieved through interference of the lower gut–liver 
axis, and notably, only after removal of the rectum. This 
suggests pathogens within the rectum may also contribute 
to pathogenesis and disease activity of PSC.
Though the pathogenesis of PSC remains poorly 
understood, the upregulation of toll-like receptors by 
biliary epithelial cells11 and the increase in circulating T 
helper 17 cells in patients with PSC12 strongly suggest the 
involvement of the gut microbiome in the pathogenesis of 
PSC. It has also been proposed that inflammation within 
the gut causes the propagation of memory T lympho-
cytes, and the subsequent recruitment and preferential 
binding of these chemokine (C-C motif) receptor 9 posi-
tive—integrin α4β7-positive T lymphocytes to abnormally 
upregulated mucosal vascular addressin cell adhesion 
molecule 1, vascular adhesion protein-1 and gut-homing 
chemokine (C-C motif) ligand (CCL25) on hepatic 
endothelial cells, cause PSC through inflammation.13 
This mechanistic model could explain why this patient 
achieved remission of her PSC after panproctocolectomy, 
and why association studies have demonstrated a protec-
tive effect against the recurrence of PSC in allograft livers 
in patients with UC who have had a colectomy.14 15
Nonetheless, as the cost of interrogating the micro-
biome becomes more affordable, longitudinal and high 
throughput screens of the microbiome in the lower GI 
tract offers the possibility of identifying the pathogenic 
microorganisms in PSC and UC. However, even if a 
pathogen is identified, mechanistic studies to identify a 
target for drug action and drug safety studies may mean 
a potential treatment could take decades to transition 
from bench to bedside. Faecal transplantation may be an 
alternative method to reverse gut dysbiosis and restore 
normal balance within the lower GI tract. Interestingly, a 
clinical trial assessing the effects of faecal transplantation 
in patients with PSC is already underway, and results of 
this study are eagerly awaited ( ClinicalTrials. gov, identi-
fier: NCT02424175).
In summary, the lower gut–liver axis is most likely 
involved in the pathogenesis of PSC. Though our under-
standing of the immune-mediated disease remains poor, 
rapid advances in basic science research that target 
the microbiome in the lower GI tract is likely to make 
headway in developing treatments for the disease.
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